2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1635 A Phase I study of atrn-119, an ATR inhibitor, in combination with decitabine in patients with TP53-mutated AML or higher-risk MDS

J. Scott Austin Beeler, MD, PhD, Jeremy T Baeten, PhD2, Ramzi Abboud, MD3, Matthew J. Christopher, MD, PhD4, Zachary D. Crees, MD5, John F. DiPersio, MD6, Meagan A. Jacoby, MD, PhD7, Giulia Petrone, MD8, Iskra Pusic, MD MSCI9, Samuel Urrutia, MD, MS10, Daniel C. Link, MD11, Geoffrey L. Uy, MD12
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States
9 Washington University School of Medicine, St. Louis, Missouri, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 Washington University School of Medicine, St. Louis, Missouri, United States
12 Washington University School of Medicine, St. Louis, Missouri, United States

Background and Significance

TP53 mutations occur in approximately 10–15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents such as decitabine have clinical activity in TP53-mutated (TP53m) myeloid neoplasms, molecular remissions are uncommon and nearly all patients relapse. The biological determinants of response and resistance to hypomethylating agents in TP53m myeloid neoplasms remain poorly understood. Our recent work (Baeten et al., Blood Adv, 2026) demonstrated that decitabine induces substantial replicative stress characterized by reduced replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia and Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53m acute myeloid leukemia (AML) cells, creating a potential therapeutic vulnerability. In preclinical models, combined decitabine and ATR inhibition induced selective synthetic lethality in TP53m AML, mediated in part by mitotic catastrophe. Combined treatment with decitabine and ATR inhibition significantly reduced leukemia burden and prolonged survival in mouse models of TP53m AML. Collectively, these findings support a mechanistic model in which TP53 loss creates a selective dependency on ATR-mediated stress response pathways during decitabine-induced replication stress, thereby providing a strong biological rationale for therapeutic targeting. We therefore hypothesize that ATRN-119, a potent and selective ATR inhibitor, will enhance sensitivity to decitabine in patients with TP53m AML and higher-risk myelodysplastic syndromes (MDS), resulting in deeper and more durable disease responses.

Study Design and Methods

NCT07617363 is an open-label, single-center, phase I study with dose-escalation and dose-expansion cohorts evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antileukemic activity of ATRN-119 in combination with decitabine in patients with TP53m AML or higher-risk MDS. TP53m disease is defined by a TP53 mutation with a variant allele frequency ≥10% or a TP53 deletion detected in ≥10% of evaluated cells. Higher-risk MDS is defined as an IPSS-R score >3.5, IPSS-M score >0.5, or bone marrow blasts ≥10%. The dose-escalation phase will enroll 6–15 adults with relapsed or refractory TP53m AML or higher-risk MDS. The dose-expansion phase will enroll 12 adults with previously untreated TP53m AML or higher-risk MDS. Eligible patients must have adequate performance status and organ function, no central nervous system disease involvement or active graft-versus-host disease, and no concomitant use of strong CYP3A4 inhibitors or inducers.

Patients will receive oral ATRN-119 once daily on days 1–28 of each 28-day cycle in combination with decitabine 20 mg/m² intravenously on days 1–5 for up to 24 cycles. Dose escalation will use a Bayesian optimal interval design with backfilling (BF-BOIN) and evaluate up to 3 dose levels. Key endpoints include the incidence and severity of adverse events, dose-limiting toxicities, complete remission rate according to ELN 2022 criteria for AML and IWG 2023 criteria for higher-risk MDS, event-free survival, overall survival, bone marrow TP53 mutation clearance, and PK. Integrated correlative studies will evaluate genomic, epigenetic, and DNA damage response biomarkers associated with response and resistance to therapy. Study endpoints will be evaluated using descriptive statistics and the Kaplan-Meier methodology. Enrollment is anticipated to begin in the third quarter of 2026 at Washington University in St. Louis, Missouri, USA. This study represents the first clinical evaluation of ATR inhibition in patients with AML and investigates a mechanism-based therapeutic strategy targeting replication stress in TP53m AML and higher-risk MDS.

J. Scott Austin Beeler, MD, PhD: No relevant conflicts of interest to declare.